Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 17/20 | 0.57 |
| ▸ | LY96 | Q9Y6Y9 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6843139 | 0.95 | TLR4 (0.51) | TLR4 | |
| SCHEMBL3925303 | 0.94 | TLR4 (0.64) | TLR4LY96 | |
| SCHEMBL3933640 | 0.94 | TLR4 (0.64) | TLR4LY96 | |
| SCHEMBL3929467 | 0.90 | TLR4 (0.58) | TLR4LY96 | |
| SCHEMBL3931918 | 0.90 | TLR4 (0.58) | TLR4LY96 | |
| SCHEMBL3937640 | 0.90 | TLR4 (0.58) | TLR4LY96 | |
| SCHEMBL3928662 | 0.90 | TLR4 (0.58) | TLR4LY96 | |
| SCHEMBL3933643 | 0.89 | TLR4 (0.57) | TLR4LY96 | |
| SCHEMBL3925310 | 0.89 | TLR4 (0.57) | TLR4LY96 | |
| SCHEMBL3936847 | 0.86 | TLR4 (0.68) | TLR4LY96 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6764840-B2 | AUGMENT ANTIBODY PRODUCTION IN IMMUNIZED ANIMALS AS WELL AS STIMULATE CYTOKINE PRODUCTION AND ACTIVATE MACROPHAGES. | CORIXA CORPORATION | 2004-07-20 | — | — | US | disclosed |
| US-20020048588-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020048588-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | DNPEP, CD68, MGAT3 | TLR4 60/4885LY96 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.